Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18941809 | NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS | November 2024 | May 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18804734 | RECOMBINANT VIRUS, COMPOSITION COMPRISING THE SAME, AND USES THEREOF | August 2024 | December 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18801071 | NUCLEIC ACID VACCINES | August 2024 | June 2025 | Abandon | 10 | 1 | 0 | Yes | No |
| 18665250 | METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES | May 2024 | September 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18654557 | COMPOSITIONS FOR USE IN TREATMENT OF ACNE | May 2024 | August 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18635203 | TROPICAL DISEASE VACCINES | April 2024 | February 2026 | Abandon | 22 | 0 | 1 | No | No |
| 18615895 | NOVEL MULTIVALENT NANOPARTICLE-BASED VACCINES | March 2024 | February 2026 | Allow | 23 | 2 | 1 | No | No |
| 18615011 | SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES | March 2024 | December 2025 | Allow | 21 | 1 | 1 | No | No |
| 18615472 | NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS | March 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18425919 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | January 2024 | August 2025 | Allow | 18 | 1 | 0 | No | No |
| 18400533 | MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE VACCINE FORMULATIONS | December 2023 | January 2026 | Allow | 24 | 2 | 1 | Yes | No |
| 18511859 | Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular Stimulator of Interferon Genes Pathway | November 2023 | December 2025 | Abandon | 25 | 3 | 0 | No | No |
| 18500926 | METHODS FOR PURIFICATION OF RECOMBINANT AAV VECTORS | November 2023 | December 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18484856 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR | October 2023 | January 2026 | Allow | 28 | 2 | 1 | No | No |
| 18481345 | OPTIMIZED HOST/VECTOR SYSTEM FOR PRODUCING PROTECTIVE MONO- AND MULTIVALENT SUBUNIT VACCINES ON THE BASIS OF THE YEAST KLUYVEROMYCES LACTIS | October 2023 | July 2025 | Allow | 21 | 1 | 1 | No | No |
| 18475942 | SCALABLE PRODUCTION METHOD FOR AAV | September 2023 | March 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18368968 | SINGLE CYCLE REPLICATING ADENOVIRUS VECTORS | September 2023 | August 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18448089 | Biological Therapeutics for Infection-Relating Disorders or Conditions | August 2023 | October 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18446965 | COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF AN ANTIBODY LIKE PROTEIN AND RIBONUCLEIC ACID | August 2023 | October 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18350646 | PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA | July 2023 | February 2026 | Abandon | 31 | 2 | 1 | No | No |
| 18349277 | GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS IIIB | July 2023 | January 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18348323 | NOVEL SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS | July 2023 | May 2025 | Allow | 22 | 2 | 1 | No | No |
| 18216118 | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | June 2023 | November 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18322679 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS | May 2023 | August 2025 | Allow | 27 | 1 | 1 | No | No |
| 18140457 | LIPIDS AS SYNTHETIC VECTORS TO ENHANCE ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY | April 2023 | April 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18298233 | METHOD TO IMPROVE VIRUS FILTRATION CAPACITY | April 2023 | May 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18115253 | LATERAL FLOW ASSAYS FOR NON-DIAGNOSTIC ANALYTES | February 2023 | August 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18021989 | ANTIVIRAL COMPOSITION AGAINST INFLUENZA A VIRUS | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18163145 | FcRn-Targeted Mucosal Vaccination Against Influenza Infections | February 2023 | January 2025 | Allow | 23 | 1 | 1 | No | No |
| 18005573 | IMPROVED CORONAVIRUS VACCINE | January 2023 | August 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18148077 | GENE THERAPY FOR CEROID LIPOFUSCINOSES | December 2022 | May 2025 | Allow | 29 | 1 | 1 | No | No |
| 18063902 | METHOD OF TREATING INFLUENZA A | December 2022 | March 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18009022 | Fusion Protein of Pentamer and GB of Cytomegalovirus, and Vaccine Containing Said Fusion Protein | December 2022 | November 2025 | Allow | 35 | 4 | 1 | Yes | No |
| 18055925 | AAV-MEDIATED EXPRESSION OF ANTI-INFLUENZA ANTIBODIES AND METHODS OF USE THEREOF | November 2022 | April 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18053927 | HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN | November 2022 | July 2024 | Allow | 20 | 1 | 1 | No | No |
| 18048827 | DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OF | October 2022 | September 2025 | Abandon | 35 | 2 | 1 | No | No |
| 18048828 | DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OF | October 2022 | February 2025 | Abandon | 28 | 1 | 1 | No | No |
| 17931017 | Recombinant Nucleic Acid Construct Encoding Influenza Peptides and Compositions | September 2022 | July 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17876682 | VACCINIA VIRAL VECTORS ENCODING CHIMERIC VIRUS LIKE PARTICLES | July 2022 | November 2024 | Allow | 27 | 1 | 1 | No | No |
| 17869776 | METHODS FOR PREVENTING DENGUE AND HEPATITIS A | July 2022 | September 2024 | Allow | 26 | 1 | 1 | No | No |
| 17835830 | INFLUENZA VIRUSES WITH MUTANT PB2 GENE SEGMENT AS LIVE ATTENUATED VACCINES | June 2022 | May 2025 | Allow | 35 | 2 | 1 | No | No |
| 17834340 | Methods and Compositions for Treating Cancer | June 2022 | November 2025 | Allow | 41 | 3 | 2 | Yes | No |
| 17756971 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | June 2022 | February 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17782951 | METHODS FOR IDENTIFYING VIRAL INFECTIONS AND FOR ANALYZING EXOSOMES IN LIQUID SAMPLES BY RAMAN SPECTROSCOPY | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17738539 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | May 2022 | September 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17737532 | INFECTIOUS DISEASE VACCINES | May 2022 | May 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17732141 | MODIFIED IMMUNIZATION VECTORS | April 2022 | February 2025 | Allow | 33 | 2 | 1 | No | No |
| 17723054 | PARAMYXOVIRUS VIRUS-LIKE PARTICLES AS PROTEIN DELIVERY VEHICLES | April 2022 | November 2024 | Allow | 31 | 3 | 1 | Yes | No |
| 17692540 | RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME | March 2022 | January 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17683171 | NUCLEIC ACID VACCINES | February 2022 | March 2025 | Abandon | 37 | 3 | 1 | Yes | No |
| 17677141 | NOVEL INFLUENZA ANTIGENS | February 2022 | December 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17591421 | LYSSAVIRUS ANTIGEN CONSTRUCTS | February 2022 | October 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17590173 | COMBINATION VACCINE | February 2022 | February 2025 | Allow | 36 | 2 | 1 | No | No |
| 17572465 | SEASONAL RNA INFLUENZA VIRUS VACCINES | January 2022 | February 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17646227 | UNIVERSAL INFLUENZA VACCINE COMPOSITIONS | December 2021 | December 2025 | Allow | 48 | 3 | 1 | No | No |
| 17542337 | PARAMYXOVIRUS VIRUS-LIKE PARTICLES AS PROTEIN DELIVERY VEHICLES | December 2021 | December 2025 | Allow | 49 | 2 | 1 | No | No |
| 17616583 | RECOMBINANT NON-STRUCTURAL PROTEIN 1, RECOMBINANT INFLUENZA VIRUS AND IMMUNOLOGICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF TREATING OR PREVENTING DISEASE OR CONDITION CAUSED BY OR ASSOCIATED WITH INFLUENZA VIRUS | December 2021 | January 2026 | Allow | 50 | 1 | 1 | No | No |
| 17616137 | Live Attenuated Universal Influenza Virus Vaccines, Methods and Uses Thereof | December 2021 | February 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17535998 | METHODS AND SYSTEMS FOR DETERMINING VIRUSES IN BIOLOGICAL SAMPLES USING A SINGLE ROUND BASED POOLING | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17527524 | METHODS AND KITS FOR THE DIAGNOSIS OF INFLUENZA | November 2021 | April 2025 | Allow | 41 | 3 | 1 | Yes | No |
| 17516462 | REAL-TIME DETECTION OF INFLUENZA VIRUS | November 2021 | April 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17510930 | ANTI-DENGUE VACCINES AND ANTIBODIES | October 2021 | April 2025 | Allow | 41 | 4 | 1 | No | No |
| 17458712 | IMMUNOGENIC COMPOSITION | August 2021 | April 2025 | Allow | 43 | 3 | 1 | No | No |
| 17399731 | PURIFICATION OF VIRUS LIKE PARTICLES | August 2021 | December 2024 | Allow | 40 | 3 | 0 | Yes | Yes |
| 17428921 | STABILIZED 9 AND 10 SEGMENTED INFLUENZA VIRUSES AS A VACCINE PLATFORM AND METHODS OF MAKING AND USING SAME | August 2021 | May 2025 | Allow | 45 | 2 | 2 | Yes | No |
| 17294603 | LIVE ATTENUATED INFLUENZA B VIRUS COMPOSITIONS METHODS OF MAKING AND USING THEREOF | May 2021 | August 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17246955 | ZIKA VIRUS TREATMENT OF CD24-POSITIVE TUMORS AND DISEASES ASSOCIATED WITH ABNORMAL T CELL ACTIVATION AND TREATING OR PREVENTING ZIKA VIRUS INFECTIONS | May 2021 | May 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17212836 | RECOMBINANT MULTIVALENT INFLUENZA VIRUSES | March 2021 | December 2024 | Allow | 45 | 3 | 1 | No | No |
| 17199972 | NOVEL ADENOVIRAL VECTOR SYSTEM FOR GENE DELIVERY | March 2021 | December 2024 | Allow | 45 | 2 | 1 | No | No |
| 17260045 | BROADLY REACTIVE IMMUNOGENS OF INFLUENZA H3 VIRUS, COMPOSITIONS AND METHODS OF USE THEREOF | January 2021 | August 2024 | Allow | 43 | 3 | 1 | No | No |
| 17259885 | METHODS FOR GENERATING PAN-EPITOPIC IMMUNOGENS OF INFLUENZA H3 VIRUS, COMPOSITIONS AND METHODS OF USE THEREOF | January 2021 | January 2026 | Abandon | 60 | 4 | 1 | No | No |
| 17252638 | MOSAIC INFLUENZA VIRUS HEMAGGLUTININ POLYPEPTIDES AND USES THEREOF | December 2020 | March 2025 | Allow | 51 | 3 | 1 | No | No |
| 17251736 | NUCLEIC ACID APTAMERS TARGETING LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND USES THEREOF | December 2020 | February 2026 | Abandon | 60 | 3 | 1 | No | No |
| 17058379 | Antigenically Stealthed Oncolytic Viruses | November 2020 | May 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17041792 | METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE | September 2020 | September 2025 | Allow | 59 | 6 | 1 | Yes | No |
| 16982356 | METHOD FOR DETERMINING VACCINE EFFICACY IN AN INDIVIDUAL AND MEANS THEREFORE | September 2020 | October 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16966345 | PSEUDORABIES VIRUS FOR TREATING TUMORS | July 2020 | June 2025 | Allow | 59 | 3 | 1 | Yes | No |
| 16959090 | GENE THERAPY FOR EOSINOPHILIC DISORDERS | June 2020 | October 2024 | Allow | 51 | 6 | 1 | Yes | No |
| 16954583 | SWINE INFLUENZA A VIRUS VACCINE | June 2020 | March 2024 | Allow | 44 | 3 | 1 | No | No |
| 16753657 | Microbiota Sequence Variants Of Tumor-Related Antigenic Epitopes | April 2020 | January 2026 | Abandon | 60 | 4 | 1 | No | No |
| 16645140 | VACCINE MOLECULES | March 2020 | December 2024 | Allow | 57 | 4 | 1 | No | No |
| 16739182 | METHODS FOR IN VITRO EVOLUTION OF CONSTRUCTS DERIVED FROM VIRUSES | January 2020 | December 2024 | Allow | 59 | 3 | 1 | No | No |
| 16607233 | Device and Method for Sample Isolation | October 2019 | July 2024 | Allow | 57 | 3 | 1 | No | No |
| 16595980 | ALPHAVIRUS-BASED REPLICONS FOR ADMINISTRATION OF BIOTHERAPEUTICS | October 2019 | February 2025 | Allow | 60 | 3 | 1 | No | No |
| 16426124 | Gene Therapy Vector Contamination Assay | May 2019 | December 2023 | Allow | 55 | 6 | 0 | No | No |
| 16210750 | METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR STIMULATING TYPE 1 INTERFERON GENES | December 2018 | January 2026 | Allow | 60 | 10 | 1 | Yes | No |
| 16098834 | INFLUENZA MRNA VACCINES | November 2018 | July 2025 | Allow | 60 | 5 | 1 | No | No |
| 16144394 | NUCLEIC ACID VACCINES | September 2018 | March 2025 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 16036318 | NUCLEIC ACID VACCINES | July 2018 | March 2025 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 16025296 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | July 2018 | May 2019 | Allow | 10 | 1 | 1 | No | No |
| 15637513 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | June 2017 | September 2017 | Allow | 2 | 1 | 0 | No | No |
| 15537109 | SYNERGISTIC CO-ADMINISTRATION OF COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR HUMAN AND AVIAN H5N1 INFLUENZA | June 2017 | October 2019 | Allow | 28 | 1 | 1 | No | No |
| 15400797 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLUENZA INFECTION | January 2017 | March 2019 | Allow | 26 | 2 | 1 | No | No |
| 15358845 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | November 2016 | July 2017 | Allow | 7 | 2 | 0 | No | No |
| 15358868 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | November 2016 | July 2017 | Allow | 7 | 2 | 0 | No | No |
| 15345697 | LECTIN COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN | November 2016 | December 2017 | Allow | 13 | 2 | 1 | No | No |
| 15290230 | T Cell Expansion | October 2016 | June 2018 | Allow | 20 | 2 | 0 | Yes | No |
| 15106292 | Influenza-Specific T-Cell Receptor and its Uses in the Detection, Prevention and/or Treatment of Influenza | June 2016 | March 2019 | Allow | 33 | 2 | 1 | No | No |
| 14973409 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | December 2015 | February 2016 | Allow | 2 | 1 | 0 | No | No |
| 14949161 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | November 2015 | April 2016 | Allow | 5 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BLUMEL, BENJAMIN P.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BLUMEL, BENJAMIN P works in Art Unit 1671 and has examined 196 patent applications in our dataset. With an allowance rate of 94.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner BLUMEL, BENJAMIN P's allowance rate of 94.9% places them in the 84% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by BLUMEL, BENJAMIN P receive 2.63 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BLUMEL, BENJAMIN P is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +6.7% benefit to allowance rate for applications examined by BLUMEL, BENJAMIN P. This interview benefit is in the 34% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 28.3% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 47.8% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 90.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 48.9% are granted (fully or in part). This grant rate is in the 45% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 23.5% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.2% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.